Correction: Mutations in the DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes

Oncotarget - United States
doi 10.18632/oncotarget.25856
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Mutations and Karyotype Predict Treatment Response in Myelodysplastic Syndromes

American Journal of Hematology
Hematology
2018English

Role of BCL2L10 Methylation and TET2 Mutations in Higher Risk Myelodysplastic Syndromes Treated With 5-Azacytidine

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

IDH1 and IDH2 Mutations in Myelodysplastic Syndromes and Role in Disease Progression

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Prognostic Significance of U2AF1 Mutations in Myelodysplastic Syndromes: A Meta-Analysis

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

A Calcium- And Calpain-Dependent Pathway Determines the Response to Lenalidomide in Myelodysplastic Syndromes

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Epigenetic Approaches in the Treatment of Myelodysplastic Syndromes: Clinical Utility of Azacitidine

OncoTargets and Therapy
OncologyPharmacology
2010English

Driver Mutations in Melanoma

Libri Oncologici
Oncology
2018English

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology
Cancer ResearchOncology
2019English

Somatic Driver Mutations in Melanoma

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy